Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




U.S. Navy Purchases Dry-Hematology Analyzers

By LabMedica International staff writers
Posted on 07 Sep 2010
The United States Navy is installing hematology analyzers on surface ships throughout the world.

The QBC STAR hematology analyzers provide users a nine-parameter complete blood count through its dry-hematology approach, which eliminates the need for liquid reagents. More...
Because of this technology, as well as the unit's small footprint and internal calibration system, the STAR can be transported easily and provide accurate patient results within minutes.

"Our line of hematology products are especially well suited for use in the military environment," commented Ken Moscone, president and CEO of QBC Diagnostics (Port Matilda, PA, USA). "With one-button operation, no start-up requirements, and the use of simple blood collection tubes, the STAR is robust, designed to go anywhere and provide results quickly. Unlike liquid reagents, dry QBC technology is not adversely affected by the pitch and roll of a ship, making it especially well-suited for use on Navy vessels."

QBC Diagnostics is a privately held company that manufactures a line of complete blood count analyzers and fluorescence microscopy products.

Related Links:

QBC Diagnostics









Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Steam Sterilizer
Hi Vac II Line
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.